Stephens initiated coverage on Thermo Fisher Scientific (NYSE:TMO) and cited the company as an industry leader in the broader life science tools/services/ diagnostics industry, with fiscal year 2023 sales of almost $42.9 billion.
The analyst highlights Thermo Fisher’s extensive product and service portfolio and its significant revenue base. Over the past decade, the company has expanded its presence in the biopharma sector through strategic mergers and acquisitions, enhancing its market exposure.
Also Read: Thermo Fisher Q2 Earnings: Marginal Revenue Dip, Completes Olink Acquisition, Lifts Annual Profit Outlook.
Thermo Fisher has around 18% share of the estimated total addressable market at more than $235 billion.
Stephens says disciplined M&A strategy and organic growth opportunities have the potential ...
